U.S. Breast Cancer Screening and Diagnostic Market Projected to Reach $2.34 Billion by 2030 – BIS Research

Market Overview: 

Market Size and Growth Rate 

The U.S. breast cancer screening and diagnostic market is valued at $1,556.6 million in 2024 and is projected to grow to $2,342.2 million by 2030, reflecting a compound annual growth rate of 7.05 percent. 

Trends & Innovation 

There has been a clear shift toward the use of digital imaging technologies, which now dominate the landscape. With the help of artificial intelligence, many screening tools now offer improved accuracy in detecting tumors, particularly in dense breast tissues. Innovations such as 3D tomosynthesis, molecular breast imaging, and portable diagnostics are helping streamline early detection. These breakthroughs also support more personalized care, with reduced turnaround times and greater diagnostic confidence. 

Access insight on U.S. breast cancer screening and diagnostic market 

Key Highlights: 

Report USP: 

• In-depth analysis of market dynamics, including drivers and restraints 
• Clear segmentation by imaging technologies, end-users, and regional distribution 
• Competitive strategies of leading companies across the value chain 
• Assessment of AI and telehealth integration into traditional screening models 

Access Free Sample Report (Including Full TOC, List of Tables, Figures, and Chart)     

Demand driver, challenges and opportunity    

Demand Drivers: 

The market is largely driven by the growing need for early breast cancer detection, a rise in public health awareness, and improved government screening programs. Technological improvements in diagnostic imaging and supportive reimbursement frameworks are making routine mammograms more accessible to a wider population. Additionally, demographic shifts, such as an aging population and changing lifestyle factors, are increasing the number of individuals at risk, creating greater demand for both initial and follow-up screenings. 

Challenges: 

Despite the strong momentum, the market faces challenges that could slow down penetration. One major obstacle is the cost associated with acquiring and maintaining advanced diagnostic equipment, which remains out of reach for many smaller or rural healthcare facilities. Another barrier is the shortage of trained radiologists and technicians, which can delay diagnoses. Moreover, there are concerns around overdiagnosis and false positives, leading to patient anxiety and potentially unnecessary treatments. This raises the importance of not just wider adoption, but also smarter application of technologies. 

Opportunities: 

There are significant opportunities for market players to address gaps in accessibility and affordability. The development of low-cost, high-accuracy portable imaging devices can serve remote areas that currently lack reliable diagnostic infrastructure. Telehealth solutions offer another route to expand reach, enabling remote consultations and second opinions through cloud-based platforms. The use of AI in reading scans can dramatically increase throughput and accuracy, helping address workforce shortages. Additionally, genomics-based diagnostics and personalized medicine are on the horizon, offering deeper insights into cancer risk and treatment response. 

Download complete TOC 

Market Segmentation: 

Segmentation 1: Technology based segmentation 

• Conventional 2D Mammography 

• Digital Breast Tomosynthesis 

• Contrast-Enhanced Digital Mammography 

• Ultrasound  

• MRI Coils  

• Others 

Competitive Landscape: 

Key Players 

•    Koninklijke Philips N.V 

•    Canon Inc 

•    Planmed Oy 

•    Siemens Healthineers AG 

•    GE Healthcare  

•    FUJIFILM Holdings Corporation 

•    Hologic, Inc. 

•    Mammotome, a Danaher Corporation company 

•    Becton, Dickinson, and Company 

•    Metaltronica S.p.A 

Strategic Initiatives 

Firms are investing in AI-enabled platforms to enhance workflow efficiency and detection rates. Others are entering collaborations with telehealth providers or public health departments to roll out mobile screening units in underserved areas. Several have launched patient education campaigns to boost screening volumes and reduce late-stage diagnoses. 

Case Studies & Success Story: 

The U.S. breast cancer screening market has seen notable success with the adoption of digital breast tomosynthesis (DBT) and enhanced MRI, significantly improving early detection especially in dense breast tissue. Hospitals using DBT report higher cancer detection rates and fewer false positives. Public health campaigns and mobile screening units have expanded access in underserved regions, leading to earlier diagnoses and improved outcomes. Meanwhile, AI tools are helping address radiologist shortages. Regulatory support has further accelerated the rollout of advanced diagnostics, making screening more equitable and effective across the U.S. 

Schedule a Call with Industry Experts 

Related Reports from BIS Research 

Medical X-Ray Detectors Market 

Gene Fusion Testing Market 

U.S. Prostate Cancer Testing Market 

About BIS Research 

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.   

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.    

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.   

Contact 

Head of Marketing   

Email: media@bisresearch.com    

BIS Research Inc.   

39111 PASEO PADRE PKWY STE 313,   

FREMONT, CA 94538-1686